OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS

Bayan K., ÇELEN M. K., DAL T., AYAZ C., TEKİN R., Akdemir İ., ...More

ACTA MEDICA MEDITERRANEA, vol.34, no.1, pp.71-75, 2018 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.19193/0393-6384_2018_1_12
  • Journal Name: ACTA MEDICA MEDITERRANEA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.71-75
  • Keywords: Hepatitis C, treatment, genotype, C VIRUS GENOTYPES, CHRONIC HEPATITIS-C, INFECTION, ABT-450/R-OMBITASVIR, RIBAVIRIN, TURKEY, EFFICACY, PROVINCE
  • Ankara University Affiliated: No

Abstract

Introduction: Achieving sustained virologic response (SVR) is critical in HCV patients. In current study, we aimed to investigate the efficacy and safety of DAA (OBV/PTV/r + DSV +/- RBV) treatment regimen in patients with HCV.